New oral anticoagulants: A view from the laboratory

American Journal of Hematology

Volumn 87, Issue SUPPL. 1, 2012, Pages

  Weitz, Jeffrey I ^a,b  

^a MCMASTER UNIVERSITY   (Canada)

^b MCMASTER UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVATED PROTEIN C; APIXABAN; BLOOD CLOTTING FACTOR 10A; BLOOD CLOTTING FACTOR 11; BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 9; DABIGATRAN ETEXILATE; FONDAPARINUX; PLACEBO; RIVAROXABAN; THROMBIN; THROMBOPLASTIN; WARFARIN; XIMELAGATRAN;

ARTICLE; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; CELL MIGRATION; CELL PROLIFERATION; CLINICAL FEATURE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG EFFICACY; DRUG EXCRETION; DRUG MEGADOSE; DRUG SAFETY; EMBOLISM; GASTROINTESTINAL HEMORRHAGE; GENETIC POLYMORPHISM; HEART ATRIUM FIBRILLATION; HEART INFARCTION; HUMAN; INFLAMMATION; INTERNATIONAL NORMALIZED RATIO; LIVER TOXICITY; LOW DRUG DOSE; MORTALITY; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); POTASSIUM INTAKE; PRIORITY JOURNAL; PROTHROMBIN TIME; STROKE; THROMBOEMBOLISM; THROMBOSIS; VENOUS THROMBOEMBOLISM;

ADMINISTRATION, ORAL; ANIMALS; ANTICOAGULANTS; BLOOD COAGULATION FACTORS; HUMANS; VITAMIN K;

EID: 84859971651     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.23139     Document Type: Article

References (20)

1. Eikelboom JW, Weitz JI. New anticoagulants. Circulation 2010; 121: 1523-1532.
2. Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009; 361: 1139-1151.
3. Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011; 365: 883-891.
4. Granger CB, Alexander JH, McMurray JJ, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2011; 365: 981-982.
5. Rezaie, AR. Prothrombin protects factor Xa in the prothrombinase complex from inhibition by the heparin-antithrombin complex. Blood 2001; 97: 2308-2313.
6. Brufatto N, Ward A, Nesheim ME. Factor Xa is highly protected from antithrombin-fondaparinux and antithrombin-enoxaparin when incorporated into the prothrombinase complex. J Thromb Haemost 2003; 1: 1258-1263.
7. Weitz JI. Factor Xa or thrombin: is thrombin a better target? J Thromb Haemost 2007; 5(Suppl 1): 65-67.
8. Weitz JI, Hudoba M, Massel D, et al. Clot-bound thrombin is protected from inhibition by heparin-antithrombin III but is susceptible to inactivation by antithrombin III-independent inhibitors. J Clin Invest 1990; 86: 385-391.
9. Ansell J. Factor Xa or thrombin: is factor Xa a better target? J Thromb Haemost 2007; 5(Suppl 1): 60-64.
10. Schulman S, Kearon C, Kakkar AK, et al. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med 2009; 361: 2342-2352.
11. EINSTEIN Investigators, Bauersachs R, Berkowitz SD, et al. Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med 2010; 363: 2499-2510.
12. Keisu M, Andersson TB. Drug-induced liver injury in humans: the case of ximelagatran. Handb Exp Pharmacol 2010; 196: 407-418.
13. Orfeo T, Gissel M, Butenas S, et al. Anticoagulants and the propagation phase of thrombin generation. PLoS One 2011; 6: e27852 (Epub ahead of print).
14. Wienen W, Stassen JM, Priepke H, et al. In-vitro profile and ex-vivo anticoagulant activity of the direct thrombin inhibitor dabigatran and its orally active prodrug, dabigatran etexilate. Thromb Haemost 2007; 98: 155-162.
15. Gerotziafas GT, Elalamy I, Depasse F, et al. In vitro inhibition of thrombin generation, after tissue factor pathway activation, by the oral, direct factor Xa inhibitor rivaroxaban. J Thromb Haemost 2007; 5: 886-888.
16. Mackman N, Taubman M. Tissue factor: past, present, and future. Arterioscler Thromb Vasc Biol 2009; 29: 1986-1988.
17. Blech S, Ebner T, Ludwig-Schwellinger E, et al. The metabolism and disposition of the oral direct thrombin inhibitor, dabigatran, in humans. Drug Metab Dispos 2008; 36: 386-399.
18. Eikelboom JW, Wallentin L, Connolly SJ, et al. Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: an analysis of the randomized evaluation of long-term anticoagulant therapy (RE-LY) trial. Circulation 2011; 123: 2363-2372.
19. Hohnloser SH, Oldgren J, Yang S, et al. Myocardial ischemic events in patients with atrial fibrillation treated with dabigatran or warfarin in the RE-LY Trial. Circulation 2012; 125: 669-676.
20. Uchino K, Hernandez AV. Dabigatran associated with higher risk of acute coronary events: meta-analysis of noninferiority randomized controlled trials. Arch Intern Med 2011; 2012 [Epub ahead of print].